The recent demonstration that VIP can, in fact, trigger migraine in those with underlying migraine [35], as well as other migraine-related behaviours in animal models [226], suggests that the VPAC1 and VPAC2 receptors may also hold therapeutic potential as migraine targets for the future. This evidence concerns the gene VIPR1 and migraine disorder.